Immune-mediated inner ear disease and parvovirus B19.
Human parvovirus B19 (HP-B19), the etiologic agent of the common childhood illness erythema infectiosum, has been implicated in systemic immune disorders. Patients presenting with sensorineural hearing loss and/or dizziness, not readily categorized, were evaluated for immune-mediated inner ear disease. Appropriate serologic studies including parvovirus B19 antibody titers were conducted. Thirty patients with suspected immune-mediated inner ear disease were treated with corticosteroid trial for 5 to 7 days, then reexamined with repeat audiogram and/or vestibular testing. Seventeen patients with clinical response were treated with long-term corticosteroids and cyclophosphamide. Six patients had positive HP-B19 immunoglobulin M (IgM) titers and 8 patients had positive parvovirus immunoglobulin G (IgG) titers. All 14 patients responded to therapy. Parvovirus B19, therefore, is a possible etiology of immune-mediated inner ear disease.
Cotter
C S
CS
Department of Otolaryngology, University of Florida, Gainesville.
Singleton
G T
GT
Corman
L C
LC
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D016731:Erythema Infectiosum / Q000150:complications* / Q000276:immunology; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007759:Labyrinth Diseases / Q000188:drug therapy / Q000276:immunology* / Q000821:virology*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D016732:Parvovirus B19, Human / Q000276:immunology*; D015837:Vestibular Diseases / Q000188:drug therapy / Q000209:etiology
D000305:Adrenal Cortex Hormones; D000914:Antibodies, Viral; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008727:Methotrexate